Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...
Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...
On December 11, 2025- Kowa Company, Ltd. initiated a phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback